サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1349438

Pharma4.0市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Pharma 4.0 Market (Technology: Artificial Intelligence [AI], Big Data Analytics, Cloud Computing, Internet of Things [IoT], and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 194 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
Pharma4.0市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年07月07日
発行: Transparency Market Research
ページ情報: 英文 194 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Pharma4.0市場- レポートの範囲

世界のPharma4.0市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2023年を基準年、2031年を予測年とし、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、Pharma4.0市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 109億米ドル
2031年の市場価値 469億米ドル
CAGR17.7%

このレポートでは、世界のPharma4.0市場の競合情勢を詳しく掘り下げています。世界のPharma4.0市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のPharma4.0市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • ポーターのファイブフォース分析
  • 規制シナリオ
  • 技術の進歩：医薬品の製造プロセス
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：テクノロジー別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：テクノロジー別、2017-2031
    • 人工知能（AI）
    • ビッグデータ分析
    • クラウドコンピューティング
    • モノのインターネット（IoT）
    • その他
  • 市場魅力分析：テクノロジー別

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：用途別、2017-2031
    • 創薬と開発
    • 臨床試験
    • 製造業
    • その他
  • 市場魅力分析：用途別

第8章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：エンドユーザー別、2017-2031
    • 製薬会社
    • バイオテクノロジー企業
    • CROとCMO
    • その他
  • 市場魅力度分析：エンドユーザー別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東およびアフリカ市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Amazon Web Services, Inc.
    • Siemens Healthineers
    • GE Healthcare
    • IBM Corporation
    • Microsoft Corporation
    • Oracle Corporation
    • ABB
    • Honeywell International Inc.
    • Cisco Systems, Inc.
図表

List of Tables

  • Table 01: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 02: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 07: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 10: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 11: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 14: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 18: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 19: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 23: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Pharma 4.0 Market Value Share, by Technology, 2022
  • Figure 03: Global Pharma 4.0 Market Value Share, by Application, 2022
  • Figure 04: Global Pharma 4.0 Market Value Share, by End-user, 2022
  • Figure 05: Global Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 06: Global Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 07: Global Pharma 4.0 Market Revenue (US$ Mn), by Artificial Intelligence (AI), 2017-2031
  • Figure 08: Global Pharma 4.0 Market Revenue (US$ Mn), by Big Data Analytics, 2017-2031
  • Figure 09: Global Pharma 4.0 Market Revenue (US$ Mn), by Cloud Computing, 2017-2031
  • Figure 10: Global Pharma 4.0 Market Revenue (US$ Mn), by Internet of Things (IoT), 2017-2031
  • Figure 11: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 12: Global Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 13: Global Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 14: Global Pharma 4.0 Market Revenue (US$ Mn), by Drug Discovery and Development, 2017-2031
  • Figure 15: Global Pharma 4.0 Market Revenue (US$ Mn), by Clinical Trials, 2017-2031
  • Figure 16: Global Pharma 4.0 Market Revenue (US$ Mn), by Manufacturing, 2017-2031
  • Figure 17: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 18: Global Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 19: Global Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 20: Global Pharma 4.0 Market Revenue (US$ Mn), by Pharmaceutical Companies, 2017-2031
  • Figure 21: Global Pharma 4.0 Market Revenue (US$ Mn), by Biotechnology Companies, 2017-2031
  • Figure 22: Global Pharma 4.0 Market Revenue (US$ Mn), by CROs and CMOs, 2017-2031
  • Figure 23: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 24: Global Pharma 4.0 Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 25: Global Pharma 4.0 Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 26: North America Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 27: North America Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 28: North America Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 29: North America Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 30: North America Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 31: North America Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 32: North America Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 33: North America Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 34: North America Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 35: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 36: Europe Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 37: Europe Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 38: Europe Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 39: Europe Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 40: Europe Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 41: Europe Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 42: Europe Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 43: Europe Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 44: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 46: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 47: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 48: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 49: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 50: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 51: Asia Pacific Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 52: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 53: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 54: Latin America Pharma 4.0 Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 55: Latin America Pharma 4.0 Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Latin America Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 57: Latin America Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 58: Latin America Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 59: Latin America Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 60: Latin America Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 61: Latin America Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 62: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 63: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 65: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 66: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 67: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 68: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 69: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 70: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031
目次
Product Code: TMRGL85095

Pharma 4.0 Market - Scope of Report

TMR's report on the global pharma 4.0 market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pharma 4.0 market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharma 4.0 market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharma 4.0 market.

Market Snapshot
Market Value in 2023US$ 10.9 Bn
Market Value in 2031US$ 46.9 Bn
CAGR17.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharma 4.0 market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharma 4.0 market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharma 4.0 market.

The report delves into the competitive landscape of the global pharma 4.0 market. Key players operating in the global pharma 4.0 market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharma 4.0 market profiled in this report.

Key Questions Answered in Global Pharma 4.0 Market Report:

  • What is the sales/revenue generated by pharma 4.0 across all regions during the forecast period?
  • What are the opportunities in the global pharma 4.0 market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Pharma 4.0 Market - Research Objectives and Research Approach

The comprehensive report on the global pharma 4.0 market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pharma 4.0 market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharma 4.0 market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharma 4.0 Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Pharma 4.0 Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Porter's Five Force Analysis
  • 5.2. Regulatory Scenario Pharma 4.0
  • 5.3. Technological Advancements: Pharmaceutical Manufacturing Processes
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Pharma 4.0 Market Analysis and Forecast, by Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Technology, 2017-2031
    • 6.3.1. Artificial Intelligence (AI)
    • 6.3.2. Big Data Analytics
    • 6.3.3. Cloud computing
    • 6.3.4. Internet of Things (IoT)
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Technology

7. Global Pharma 4.0 Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Drug Discovery and Development
    • 7.3.2. Clinical Trials
    • 7.3.3. Manufacturing
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Pharma 4.0 Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Pharmaceutical Companies
    • 8.3.2. Biotechnology Companies
    • 8.3.3. CROs and CMOs
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Pharma 4.0 Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Pharma 4.0 Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Technology, 2017-2031
    • 10.2.1. Artificial Intelligence (AI)
    • 10.2.2. Big Data Analytics
    • 10.2.3. Cloud computing
    • 10.2.4. Internet of Things (IoT)
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Drug Discovery and Development
    • 10.3.2. Clinical Trials
    • 10.3.3. Manufacturing
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Pharmaceutical Companies
    • 10.4.2. Biotechnology Companies
    • 10.4.3. CROs and CMOs
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Technology
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Pharma 4.0 Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Technology, 2017-2031
    • 11.2.1. Artificial Intelligence (AI)
    • 11.2.2. Big Data Analytics
    • 11.2.3. Cloud computing
    • 11.2.4. Internet of Things (IoT)
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Drug Discovery and Development
    • 11.3.2. Clinical Trials
    • 11.3.3. Manufacturing
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Pharmaceutical Companies
    • 11.4.2. Biotechnology Companies
    • 11.4.3. CROs and CMOs
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Technology
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Pharma 4.0 Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Technology, 2017-2031
    • 12.2.1. Artificial Intelligence (AI)
    • 12.2.2. Big Data Analytics
    • 12.2.3. Cloud computing
    • 12.2.4. Internet of Things (IoT)
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Drug Discovery and Development
    • 12.3.2. Clinical Trials
    • 12.3.3. Manufacturing
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Pharmaceutical Companies
    • 12.4.2. Biotechnology Companies
    • 12.4.3. CROs and CMOs
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Technology
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Pharma 4.0 Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Technology, 2017-2031
    • 13.2.1. Artificial Intelligence (AI)
    • 13.2.2. Big Data Analytics
    • 13.2.3. Cloud computing
    • 13.2.4. Internet of Things (IoT)
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Drug Discovery and Development
    • 13.3.2. Clinical Trials
    • 13.3.3. Manufacturing
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Pharmaceutical Companies
    • 13.4.2. Biotechnology Companies
    • 13.4.3. CROs and CMOs
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Technology
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Pharma 4.0 Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Technology, 2017-2031
    • 14.2.1. Artificial Intelligence (AI)
    • 14.2.2. Big Data Analytics
    • 14.2.3. Cloud computing
    • 14.2.4. Internet of Things (IoT)
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Drug Discovery and Development
    • 14.3.2. Clinical Trials
    • 14.3.3. Manufacturing
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Pharmaceutical Companies
    • 14.4.2. Biotechnology Companies
    • 14.4.3. CROs and CMOs
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Technology
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Amazon Web Services, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Type Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Siemens Healthineers
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Type Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. GE Healthcare
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Type Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. IBM Corporation
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Type Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Microsoft Corporation
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Type Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Oracle Corporation
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Type Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. ABB
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Type Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Honeywell International Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Type Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Cisco Systems, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Type Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview